Seattle-based Dendreon (NASDAQ: [[ticker:DNDN]]), the maker of an immune-boosting therapy for prostate cancer, said today it generated $28.1 million in revenue in the quarter that ended March 30. Dendreon also said it had $15 million in sales in the month of April, which reflects its increased manufacturing capacity for making sipuleucel-T (Provenge) at a factory in New Jersey. The company reiterated that it plans to generate $350 million to $400 million in sales this year. The company had a net loss of $112 million in the first quarter, and ended March with $779 million of cash and investments in the bank.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
